

Corporate Sponsored Presentations

Session Time (CDT)/ Location	Abstract #/Title/Lead Author	Type/Session Category & Title
Friday, June 3, 2022		
Friday, June 3, 2022 1:00 PM - 4:00 PM Oral Presentation: 2:00 PM	7503 / Brentuximab Vedotin ECHELON-1 First-line brentuximab vedotin plus chemotherapy to improve overall survival in patients with stage III/IV classical Hodgkin lymphoma: An updated analysis of ECHELON-1 Lead Author: S.M. Ansell	Oral Abstract Session Hematologic Malignancies – Lymphoma and Chronic Lymphocytic Leukemia
Saturday, June 4, 2022		
Saturday, June 4, 2022 8:00 AM - 11:00 AM	7559 / Brentuximab Vedotin ECHELON-3 Brentuximab vedotin in combination with lenalidomide and rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma: Safety and efficacy results from the safety run-in period of the phase 3 ECHELON-3 study Lead Author: N. Bartlett	Poster Session Hematologic Malignancies – Lymphoma and Chronic Lymphocytic Leukemia
Saturday, June 4, 2022 1:15 PM - 4:15 PM	4582 / Enfortumab Vedotin EV-103 Cohort H Study EV-103 Cohort H: Antitumor activity of neoadjuvant treatment with enfortumab vedotin monotherapy in patients with muscle-invasive bladder cancer who are cisplatin-ineligible Lead Author: D. Petrylak	Poster Session Genitourinary Cancer – Kidney and Bladder
Saturday, June 4, 2022 1:15 PM - 4:15 PM	4575 / Enfortumab Vedotin EV-HEOR-OSM Benchmarking maintenance therapy survival in first-line advanced urothelial carcinoma using disease modeling Lead Author: M. Galsky	Poster Session Genitourinary Cancer – Kidney and Bladder
Saturday, June 4, 2022 1:15 PM - 4:15 PM	4565 / Enfortumab Vedotin EV-HEOR-14D Real-world treatment patterns and clinical outcomes with first-line therapy in cisplatin-eligible and ineligible patients with advanced urothelial carcinoma Lead Author: G.P. Sonpavde	Poster Session Genitourinary Cancer – Kidney and Bladder
Saturday June 4, 2022 1:15 - 4:15 PM	TPS5603 / Tisotumab Vedotin innovaTV 205 TIP Trial in progress update on ENGOT-cx8/GOG-3024/innovaTV 205: Addition of a new cohort with first-line (1L) tisotumab vedotin (TV) + pembrolizumab (pembro) + carboplatin (carbo) ± bevacizumab (bev) in recurrent/metastatic cervical cancer (r/mCC) Lead Author: I. Vergote	Poster Session Gynecologic Cancer
Saturday June 4, 2022 1:15 - 4:15 PM	5532 / Tisotumab Vedotin HEOR Factors associated with receipt of second-line recurrent or metastatic cervical cancer treatment in the United States: A retrospective administrative claims analysis Lead Author: K. Sonawane	Poster Session Gynecologic Cancer
Saturday, June 4, 2022 4:30 PM - 6:00 PM; 1:15 PM - 4:15 PM	4516 / Enfortumab Vedotin EV-301 Long-term outcomes in EV-301: 24-month findings from the phase 3 trial of enfortumab vedotin versus chemotherapy in patients with previously treated advanced urothelial carcinoma Lead Author: J.E. Rosenberg	Poster Discussion Session Genitourinary Cancer – Kidney and Bladder
Saturday, June 4, 2022 4:30 PM - 6:00 PM; 1:15 PM - 4:15 PM	5523 / Tisotumab Vedotin HEOR Cervical cancer geographical burden analyzer: An interactive, open-access tool for understanding geographical disease burden in patients with recurrent or metastatic cervical cancer Lead Author: T. Castellano	Poster Discussion Session Gynecologic Cancer
Saturday, June 4, 2022 4:30 PM - 6:00 PM; 1:15 PM - 4:15 PM	4520 / Disitamab Vedotin (RemeGen) RC48-ADC for metastatic urothelial carcinoma with HER2-positive: Combined analysis of RC48-C005 and RC48-C009 trials Lead Author: X. Sheng	Poster Discussion Session Genitourinary Cancer – Kidney and Bladder
Sunday, June 5, 2022		
Sunday, June 5, 2022 8:00 AM - 11:00 AM	TPS3155 / SGN-B7H4V SGNB7H4V-001 TIP Phase 1 study of SGN-B7H4V, a novel, investigational vedotin antibody–drug conjugate directed to B7-H4, in patients with advanced solid tumors (SGNB7H4V-001, trial in progress) Lead Author: A. Patnaik	Poster Session Developmental Therapeutics – Molecularly Targeted Agents and Tumor Biology
Sunday, June 5, 2022 8:00 AM - 11:00 AM	TPS3154 / SGN-PDL1V SGNPDL1V-001 TIP Phase 1 study of SGN-PDL1V, a novel, investigational vedotin antibody–drug conjugate directed to PD-L1, in patients with advanced solid tumors (SGNPDL1V-001, trial in progress) Lead Author: A. Patnaik	Poster Session Developmental Therapeutics – Molecularly Targeted Agents and Tumor Biology
Sunday, June 5, 2022 8:00 AM - 11:00 AM	TPS3159 / SGN-ALPV SGNALPV-001 TIP Phase 1 study of SGN-ALPV, a novel, investigational vedotin antibody–drug conjugate directed to ALPP/ALPPL2 in advanced solid tumors (SGNALPV-001, trial in progress) Lead Author: N. Lakhani	Poster Session Developmental Therapeutics – Molecularly Targeted Agents and Tumor Biology
Monday, June 6, 2022		
Monday, June 6, 2022 8:00 AM - 11:00 AM	TPS1108 / Tucatinib HER2CLIMB-05 TIP Phase 3 study of tucatinib or placebo in combination with trastuzumab and pertuzumab as maintenance therapy for HER2+ metastatic breast cancer (HER2CLIMB-05, trial in progress) Lead Author: E. Hamilton	Poster Session Breast Cancer – Metastatic
Monday, June 6, 2022 8:00 AM - 11:00 AM	TPS1111 / Tucatinib HER2CLIMB-04 TIP Phase 2 trial of tucatinib plus trastuzumab deruxtecan in patients with HER2+ locally advanced or metastatic breast cancer with and without brain metastases (HER2CLIMB-04, trial in progress) Lead Author: I. Krop	Poster Session Breast Cancer – Metastatic
Monday June 6, 2022 8:00 AM - 11:00 AM Oral Presentation: 10:12 AM	5507 / Tisotumab Vedotin innovaTV 205 Tisotumab vedotin (TV) + pembrolizumab (pembro) in first-line (1L) recurrent or metastatic cervical cancer (r/mCC): Interim results of ENGOT Cx8/GOG 3024/innovaTV 205 Lead Author: D. Lorusso	Oral Abstract Session Gynecologic Cancer
Monday, June 6, 2022 8:00 AM - 11:00 AM	TPS1127 / Ladiratuzumab Vedotin SGNLVA-002 TIP Phase 1b/2 study of ladiratuzumab vedotin (LV) in combination with pembrolizumab for first-line treatment of triple-negative breast cancer (SGNLVA-002, trial in progress) Lead Author: J. Meisel	Poster Session Breast Cancer – Metastatic
Monday June 6, 2022 1:15 PM - 4:15 PM	TPS6100 / Tisotumab Vedotin innovaTV 207 TIP innovaTV 207: New combination dosing cohorts in the open label phase 2 study of tisotumab vedotin in solid tumors Lead Author: X. Le	Poster Session Head & Neck Cancer

The safety and efficacy of these investigational compounds, or investigational uses of marketed products, have not been established. For an agent(s) whose safety and efficacy has not been established or confirmed, future regulatory approval or commercial availability is not guaranteed.

IST Presentations

Session Time (CDT)/ Location	Abstract #/Title/Lead Author	Type/Session Category & Title
Friday, June 3, 2022		
Friday, June 3, 2022 1:00 PM - 4:00 PM Oral Presentation: 2:12 PM	7504 / Brentuximab Vedotin AHOD1331 Brentuximab vedotin and association with event-free survival (EFS) in children with newly diagnosed high-risk Hodgkin lymphoma (HL): A report from the Children's Oncology Group phase 3 study AHOD1331 (NCT 02166463) Lead Author: S.M. Castellino	Oral Abstract Session Hematologic Malignancies – Lymphoma and Chronic Lymphocytic Leukemia
Saturday, June 4, 2022		
Saturday, June 4, 2022 4:30 PM - 6:00 PM; 1:15 PM - 4:15 PM	TPS7589 / Brentuximab Vedotin SGN35-IST-054 Brentuximab vedotin and nivolumab alone and then combined with rituximab, cyclophosphamide, doxorubicin, and prednisone for frontline therapy of patients with primary mediastinal large B-cell lymphoma Lead Author: R.E. Steiner	Poster Session Hematologic Malignancies – Lymphoma and Chronic Lymphocytic Leukemia
Saturday, June 4, 2022 4:30 PM - 6:00 PM; 1:15 PM - 4:15 PM	4519 / Disitamab Vedotin IST-RC48-C011 A phase II study of RC48-ADC in HER2-negative patients with locally advanced or metastatic urothelial carcinoma Lead Author: H. Xu	Poster Discussion Session Genitourinary Cancer – Kidney and Bladder
Saturday, June 4, 2022 4:30 PM - 6:00 PM; 1:15 PM - 4:15 PM	4518 / Disitamab Vedotin IST-RC48-C014 Preliminary results of a phase Ib/II combination study of RC48-ADC, a novel humanized anti-HER2 antibody-drug conjugate (ADC) with toripalimab, a humanized IgG4 mAb against programmed death-1 (PD-1) in patients with locally advanced or metastatic urothelial carcinoma Lead Author: X. Sheng	Poster Discussion Session Genitourinary Cancer – Kidney and Bladder

The safety and efficacy of these investigational compounds, or investigational uses of marketed products, have not been established. For an agent(s) whose safety and efficacy has not been established or confirmed, future regulatory approval or commercial availability is not guaranteed.